NunaBio is proud to share that it has won the Medilink North of England Healthcare Business Awards 2026 – Investment Award.
The award was presented at Cutlers’ Hall in Sheffield, with CEO Joe Hedley accepting it on behalf of the team. The win came on the same day NunaBio announced its £6.5 million investment round, making it an especially memorable milestone for the company.
The Investment Award recognises businesses that have attracted strong investor interest by combining innovative technology with clear commercial potential. For NunaBio, it reflects growing global confidence in the company’s approach to DNA synthesis and its ability to unlock new levels of complexity, customisation and scale that aren’t possible with traditional methods.
Across research, healthcare and industrial biotechnology, demand for high‑quality, complex DNA is accelerating. NunaBio’s technology is being developed to meet that demand head‑on, with the ambition to disrupt established markets and redefine how DNA is manufactured.
The award is very much a team achievement and from early R&D through to operations, strategy and delivery, everyone at NunaBio has contributed to building the momentum that led to both the investment round and this recognition.
NunaBio would like to thank Medilink North of England for recognising our work. With fresh investment secured and growing external validation, we’re excited to continue building the next phase of NunaBio.
